<p>Hyderabad-based Natco Pharma has launched a cut-price version of an anti-cancer drug Ibrutinib, according to a report by <em>The Economic Times.</em></p>.<p>The launch of Ibrutinib, under Natco's own brand name Ibrunat, is likely to bring down the cost of anti-cancer drugs. Ibrutinib is used to treat patients with leukaemia and similar other indications of cancer.</p>.<p>As per the report, the patent for the drug is will be held by Pharmacyclics for three to four more years in India, while the marketing right will be with Johnson & Johnson. In 2015,</p>.<p>Pharmacyclics was globally acquired by US giant AbbVie in a massive $21 billion deal.</p>.<p>The Natco drug will cost approximately Rs 38,000 per month as opposed to the Rs 4 lakh course of the innovator. A patient is expected to take four tablets each day.<br /> </p>
<p>Hyderabad-based Natco Pharma has launched a cut-price version of an anti-cancer drug Ibrutinib, according to a report by <em>The Economic Times.</em></p>.<p>The launch of Ibrutinib, under Natco's own brand name Ibrunat, is likely to bring down the cost of anti-cancer drugs. Ibrutinib is used to treat patients with leukaemia and similar other indications of cancer.</p>.<p>As per the report, the patent for the drug is will be held by Pharmacyclics for three to four more years in India, while the marketing right will be with Johnson & Johnson. In 2015,</p>.<p>Pharmacyclics was globally acquired by US giant AbbVie in a massive $21 billion deal.</p>.<p>The Natco drug will cost approximately Rs 38,000 per month as opposed to the Rs 4 lakh course of the innovator. A patient is expected to take four tablets each day.<br /> </p>